Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Biocryst Pharmaceuticals Inc (BCRX) Stock Chart
BCRX Interactive Stock Chart
Interactive stock chart for Biocryst Pharmaceuticals Inc (BCRX) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $9.19. 52-week high: $11.19. 52-week low: $6.24. 50-day moving average: $9.00. 200-day moving average: $7.88.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for BCRX. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Biocryst Pharmaceuticals Inc's investment potential.